EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Readiness quiz

What should you know before taking the quiz?

Dose Diligence research deskSection 08 · Page 2 of 22Last updated 17 Nov 2026

Assess the exact arrangement—not a supplier’s brand name or an entire clinic network at once. For this assessment, distinguish three operating models:

Model being assessedFocus of this assessment
Purchasing clinic stockProduct and account eligibility, purchasing terms, receiving, storage, traceability and permitted use
Appointing a dispensing partnerPharmacy identity, destination-state permissions, prescription fulfilment, patient support and reporting
Facilitating patient accessProgramme eligibility, prescribing workflow, patient payment, communications and exception handling

Complete a separate assessment when the supplier, facility, product, legal pathway or state coverage differs materially. Do not average a well-documented arrangement with an unresolved one.

Which regulatory assumptions must not be carried forward?

FDA’s April 1, 2026 clarification states that semaglutide and tirzepatide do not appear on its drug-shortage list or 503B bulks list. It also explains that patient-specific prescribing and restrictions on essentially copying commercially available drugs are separate conditions; adding B12 is not an automatic exemption. Treat this as dated source evidence, and refresh the relevant records before commitment. (fda.gov)

FDA announced a proposal, rather than a final determination, on April 30, 2026 to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list. Do not represent that announcement as a final rule or as permission to compound while a proposal is considered. This research is not a comprehensive litigation or docket-status opinion. (fda.gov)

FDA also cautions against describing compounded medicines as FDA-approved generics or claiming that a pharmacy or outsourcing facility is FDA-approved. Those assertions should not substitute for product-specific diligence. (fda.gov)

Explore the table row by row

A working view of the research

Purchasing clinic stock

Focus of this assessment
Product and account eligibility, purchasing terms, receiving, storage, traceability and permitted use

Sources cited on this page

  1. fda.gov · Source 1 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  2. fda.gov · Source 2 ↗https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
  3. fda.gov · Source 3 ↗https://www.fda.gov/drugs/human-drug-compounding/fda-telehealth-companies-what-know-when-promoting-compounded-drugs
Section sources →